Company research
CATALYST PHARMACEUTICALS INC
CPRX
- Current Tracked Holders
- 1
- One-Year Insider Activity
-
Purchases 0 $0Sales 10 $5.8M
MARKET DATA UNAVAILABLE
No verified exchange listing
A TradingView symbol could not be derived from the cached SEC company directory. The page remains available without guessing a security.
Quarter-End Change Analysis
No published quarterly analysis yet
Reviewed research will appear here when it is published.
Current reported holders
| Portfolio Manager | Recent activity | Shares | Value | Portfolio |
|---|---|---|---|---|
| Terry SmithFundsmith LLP | CPRXReduced | 844,887 | $20,919,000 | 0.16% |
Long-term company research
Fundamental analysis
Research pending
Fundamental research pending
Reviewed company research will appear here when available.
Insider activity
One-year insider activity
Open-market purchases and sales only.
Checked 2026-08-11
| Date | Insider | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|
| 2025-12-12 | Harper MollyDirector | Sale | 15,527 | $23 | $360,195 | SEC ↗ |
| 2025-12-12 | Harper MollyDirector | Sale | 4,473 | $24 | $106,162 | SEC ↗ |
| 2025-12-12 | Harper MollyDirector | Sale | 6,746 | $23 | $155,563 | SEC ↗ |
| 2025-11-26 | Del Carmen JeffreyChief Commercial Officer | Sale | 10,983 | $23 | $256,244 | SEC ↗ |
| 2025-09-08 | Elsbernd BrianChief Compliance/Legal Officer | Sale | 30,000 | $20 | $609,000 | SEC ↗ |
| 2025-09-04 | Elsbernd BrianChief Compliance/Legal Officer | Sale | 30,000 | $20 | $585,600 | SEC ↗ |
| 2025-09-03 | Elsbernd BrianChief Compliance/Legal Officer | Sale | 20,000 | $20 | $401,600 | SEC ↗ |
| 2025-08-27 | Tierney David SDirector | Sale | 26,000 | $20 | $525,200 | SEC ↗ |
| 2025-08-26 | Miller SteveChief Op. & Scientific Officer | Sale | 115,000 | $20 | $2.3M | SEC ↗ |
| 2025-08-26 | Daly Richard JDirector, President and CEO | Sale | 22,970 | $21 | $473,641 | SEC ↗ |